Introduction: To test the hypothesis that basal total testosterone (TT) levels are associated with International Society of Urologic Pathology (ISUP) tumor grade groups at the time of diagnosis of prostate cancer (PCA). Methods: From November 2014 to March 2018, preoperative TT and PSA were measured in 601 consecutive patients who were not under androgen deprivation and undergoing surgery for PCA. Patients were classified into low (ISUP 1; reference group), intermediate (ISUP 2/3), and high (ISUP 4/5) tumor grade groups. The association of TT and other clinical factors with tumor groups was evaluated by multinomial multivariate regression analysis. Results: 218 patients (36.3%) were biopsy low grade (ISUP 1), 297 (49.4%) intermediate grade (ISUP 2/3), and 86 (14.3) high grade (ISUP 4/5). Median basal circulating TT levels progressively increased as tumor grade groups increased. On multivariate models, TT, among other clinical factors, was positively associated with the risk of intermediate (OR 1.001; p = 0.023) and high tumor grades (OR 1.002, p = 0.022) compared to low-grade cancers. Conclusions: Increased endogenous circulating basal TT levels were positively associated with ISUP tumor grade groups at the time of diagnosis indicating a close association with tumor biology. Basal TT levels may reflect the heterogeneity of the cancer population.

Keywords:
Prostate cancer, Tumor grade group, Tumor grade, Total testosterone
1.
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.
CA Cancer J Clin
. 1972 Jul–Aug;22(4):232–40.
2.
Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, et al.; European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.
J Clin Endocrinol Metab
. 2008 Jul;93(7):2737–45.
3.
Porcaro AB, De Luyk N, Corsi P, Sebben M, Tafuri A, Cacciamani G, et al. Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.
Curr Urol
. 2017 Jul;10(2):72–80.
4.
Porcaro AB, De Luyk N, Corsi P, Sebben M, Tafuri A, Processali T, et al. Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer.
Urol Int
. 2017;99(2):215–21.
5.
Porcaro AB, Petroziello A, Brunelli M, De Luyk N, Cacciamani G, Corsi P, et al. High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy.
Urol Int
. 2016;96(4):470–8.
6.
Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy.
Cancer
. 2011 Sep;117(17):3953–62.
7.
Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
J Urol
. 2003 May;169(5):1670–5.
8.
Dai B, Qu Y, Kong Y, Ye D, Yao X, Zhang S, et al. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8–10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.
BJU Int
. 2012 Dec;110(11 Pt B):E667–72.
9.
Ferro M, Lucarelli G, Bruzzese D, Di Lorenzo G, Perdonà S, Autorino R, et al. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Oncotarget
. 2017 Mar;8(11):18424–34.
10.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
JAMA
. 1998 Sep;280(11):969–74.
11.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Am J Surg Pathol
. 2016 Feb;40(2):244–52.
12.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
Ann Surg Oncol
. 2010 Jun;17(6):1471–4.
13.
Menon M, Tewari A, Peabody J; VIP Team. Vattikuti Institute prostatectomy: technique.
J Urol
. 2003 Jun;169(6):2289–92.
14.
Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique.
J Urol
. 1998 Dec;160(6 Pt 2):2418–24.
15.
Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.
Eur Urol
. 2012 Mar;61(3):480–7.
16.
Porcaro AB, de Luyk N, Corsi P, Sebben M, Tafuri A, Mattevi D, et al.; Clinical Factors Predicting and Stratifying the Risk of Lymph Node Invasion in Localized Prostate Cancer. Clinical Factors Predicting and Stratifying the Risk of Lymph Node Invasion in Localized Prostate Cancer.
Urol Int
. 2017;99(2):207–14.
17.
Porcaro AB, de Luyk N, Corsi P, Sebben M, Tafuri A, Tamanini I, et al. Bilateral lymph node micrometastases and seminal vesicle invasion associated with same clinical predictors in localized prostate cancer.
Tumori
. 2017 May;103(3):299–306.
18.
Porcaro AB, Siracusano S, de Luyk N, Corsi P, Sebben M, Tafuri A, et al. Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System.
Curr Urol
. 2017 Aug;10(3):118–25.
19.
Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, et al.; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with carcinoma of the prostate gland.
Arch Pathol Lab Med
. 2009 Oct;133(10):1568–76.
20.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Eur Urol
. 2017 Apr;71(4):618–29.
21.
Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.
J Urol
. 2015 Feb;193(2):403–13.
22.
Zagars GK, Pollack A, von Eschenbach AC. Serum testosterone–a significant determinant of metastatic relapse for irradiated localized prostate cancer.
Urology
. 1997 Mar;49(3):327–34.
23.
Imamoto T, Suzuki H, Akakura K, Komiya A, Nakamachi H, Ichikawa T, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer.
Endocr J
. 2001 Oct;48(5):573–8.
24.
Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis.
J Clin Oncol
. 2000 Feb;18(4):847–53.
25.
Porcaro AB, Tafuri A, Sebben M, Corsi P, Pocessali T, Pirozzi M, et al. Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy.
Urol Int
. 2018;101(1):38–46.
26.
Wang K, Chen X, Bird VY, Gerke TA, Manini TM, Prosperi M. Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients’ data with prostatic diseases.
Int J Cancer
. 2017 Nov;141(9):1783–93.
27.
Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, et al. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.
Clin Cancer Res
. 2012 Jul;18(13):3648–57.
28.
Smals AG, Kloppenborg PW, Benraad TJ. Circannual cycle in plasma testosterone levels in man.
J Clin Endocrinol Metab
. 1976 May;42(5):979–82.
29.
Porcaro AB, Tafuri A, Sebben M, Cacciamani G, Ghimenton C, Brunelli M, et al. Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease.
Urol Int
. 2019 Feb:1–9.
30.
Bandini M, Gandaglia G, Briganti A. Obesity and prostate cancer.
Curr Opin Urol
. 2017 Sep;27(5):415–21.
31.
Vicentini C, Cantù C, Antonello D, Simbolo M, Mafficini A, Luchini C, et al. ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.
Pathol Res Pract
. 2018 Oct;214(10):1675–80.
32.
Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.
BJU Int
. 2010 Mar;105(6):824–9.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.